Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy - STABILITY


Darapladib is a novel oral lipoprotein phospholipase A2 (Lp-PLA2) inhibitor with favorable effects on atherosclerotic lesions in animal studies. It is considered to be a potent anti-inflammatory agent by interfering with arachidonic acid metabolism. The current trial sought to study the safety and efficacy of darapladib in patients with chronic coronary artery disease (CAD).